Core Viewpoint - The company reported a revenue of 1.459 billion yuan for the first half of 2025, reflecting a year-on-year growth of 2.74%, while net profit attributable to shareholders decreased by 66.12% to 14.6675 million yuan [1] Group 1: Financial Performance - The company's revenue for the reporting period was 1.459 billion yuan, showing a growth of 2.74% compared to the previous year [1] - The net profit attributable to shareholders was 14.6675 million yuan, which represents a significant decline of 66.12% year-on-year [1] Group 2: Business Expansion - The company is in an accelerated expansion phase, having opened 17 new medical institutions over the past three years, which lays a solid foundation for future performance growth [1] - New hospitals require a nurturing period of three to five years before becoming fully operational, leading to initial operational costs and expenses that impact short-term profitability [1]
普瑞眼科上半年净利同比下降逾六成